AstraZeneca PLC
AZN
$189.90
-$2.60-1.35%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 45.34% | 44.71% | 28.80% | 22.76% | 18.14% |
| Total Depreciation and Amortization | 8.25% | -12.07% | 3.92% | 2.77% | 2.68% |
| Total Amortization of Deferred Charges | 18.00% | -28.57% | -28.57% | -28.57% | -28.57% |
| Total Other Non-Cash Items | -126.21% | 272.26% | 181.72% | 169.73% | 151.68% |
| Change in Net Operating Assets | -27.32% | 27.23% | -333.26% | -117.63% | -397.67% |
| Cash from Operations | 22.88% | 33.58% | 21.00% | 34.96% | 14.65% |
| Capital Expenditure | -46.05% | -42.56% | -34.69% | -26.45% | -41.37% |
| Sale of Property, Plant, and Equipment | -76.36% | -77.78% | -79.66% | -95.00% | -58.33% |
| Cash Acquisitions | 67.48% | 66.94% | 68.77% | -97.16% | -244.13% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -19.41% | -15.29% | -18.72% | 20.94% | -34.16% |
| Cash from Investing | 14.69% | 16.92% | 20.14% | -30.38% | -96.36% |
| Total Debt Issued | -94.16% | -88.49% | -90.01% | -73.24% | 63.24% |
| Total Debt Repaid | 51.97% | 92.14% | 46.13% | -55.37% | 4.05% |
| Issuance of Common Stock | 5.26% | 11.11% | 8.33% | 14.29% | 15.15% |
| Repurchase of Common Stock | -543.21% | -527.16% | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -7.32% | -7.41% | -10.62% | -10.66% | -3.30% |
| Other Financing Activities | 76.90% | 108.81% | 111.16% | 111.39% | 4.74% |
| Cash from Financing | -88.79% | -36.42% | -216.19% | -248.13% | 39.15% |
| Foreign Exchange rate Adjustments | 149.46% | 26.92% | 120.00% | 76.84% | -55.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 229.33% | 2,080.98% | -70.56% | -233.32% | 39.88% |